S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
Log in

Aptorum Group Stock Forecast, Price & News

+0.46 (+16.14 %)
(As of 01/15/2021 12:00 AM ET)
Today's Range
Now: $3.31
50-Day Range
MA: $2.61
52-Week Range
Now: $3.31
Volume855,971 shs
Average Volume174,252 shs
Market Capitalization$112.57 million
P/E RatioN/A
Dividend YieldN/A
Aptorum Group Limited, a pharmaceutical company, engages in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly infectious diseases and cancers. Its pipeline through the establishment of drug discovery platforms enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. The company is also pursuing therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. It also has projects focused on surgical robotics and natural supplement for women undergoing menopause and experiencing related symptoms. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.


Overall MarketRank

0.52 out of 5 stars

Medical Sector

1258th out of 1,480 stocks

Pharmaceutical Preparations Industry

555th out of 612 stocks

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:APM



Sales & Book Value

Annual Sales$540,000.00
Book Value$0.51 per share



Market Cap$112.57 million
Next Earnings Date5/5/2021 (Estimated)
OptionableNot Optionable
+0.46 (+16.14 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive APM News and Ratings via Email

Sign-up to receive the latest news and ratings for APM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Aptorum Group (NASDAQ:APM) Frequently Asked Questions

How has Aptorum Group's stock price been impacted by Coronavirus?

Aptorum Group's stock was trading at $2.93 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, APM stock has increased by 13.0% and is now trading at $3.31.
View which stocks have been most impacted by COVID-19

Is Aptorum Group a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aptorum Group in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Aptorum Group stock.
View analyst ratings for Aptorum Group
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Aptorum Group?

Wall Street analysts have given Aptorum Group a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Aptorum Group wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Aptorum Group's next earnings date?

Aptorum Group is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Aptorum Group

Are investors shorting Aptorum Group?

Aptorum Group saw a drop in short interest in the month of December. As of December 31st, there was short interest totaling 76,700 shares, a drop of 61.9% from the December 15th total of 201,200 shares. Based on an average daily volume of 1,660,000 shares, the days-to-cover ratio is presently 0.0 days. Approximately 0.9% of the shares of the company are short sold.
View Aptorum Group's Short Interest

Who are some of Aptorum Group's key competitors?

What other stocks do shareholders of Aptorum Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptorum Group investors own include Gilead Sciences (GILD), SCYNEXIS (SCYX), Cidara Therapeutics (CDTX), Quest Diagnostics (DGX), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), (MRNA), Micron Technology (MU), (SNY) and Aridis Pharmaceuticals (ARDS).

Who are Aptorum Group's key executives?

Aptorum Group's management team includes the following people:
  • Mr. Chung Yuen Huen, Founder, Chairman & CEO (Age 40, Pay $441.79k)
  • Mr. Darren Lui, Pres & Exec. Director (Age 39, Pay $389.79k)
  • Ms. Sabrina Khan, Chief Financial Officer (Age 39, Pay $322.64k)
  • Dr. Siu-yan Ng, Chief Operating Officer (Age 39, Pay $113.99k)
  • Dr. Clark Cheng, Chief Medical Officer & Exec. Director (Age 40, Pay $432.47k)
  • Prof. Wai Yip Lee, Head of R&D (Age 47, Pay $372.4k)

What is Aptorum Group's stock symbol?

Aptorum Group trades on the NASDAQ under the ticker symbol "APM."

How do I buy shares of Aptorum Group?

Shares of APM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aptorum Group's stock price today?

One share of APM stock can currently be purchased for approximately $3.31.

How big of a company is Aptorum Group?

Aptorum Group has a market capitalization of $112.58 million and generates $540,000.00 in revenue each year. Aptorum Group employs 36 workers across the globe.

What is Aptorum Group's official website?

The official website for Aptorum Group is www.aptorumgroup.com.

How can I contact Aptorum Group?

Aptorum Group's mailing address is 17/F GUANGDONG INVESTMENT TOWER 148 CONNAUGHT ROAD CENTRAL, HONG KONG K3, 999077. The company can be reached via phone at 442080929299 or via email at [email protected]

This page was last updated on 1/16/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.